Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9449486rdf:typepubmed:Citationlld:pubmed
pubmed-article:9449486lifeskim:mentionsumls-concept:C0024314lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C0221912lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C0054950lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C1334894lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C1332080lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C1515757lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C1456796lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C1705984lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C0162768lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C1538092lld:lifeskim
pubmed-article:9449486lifeskim:mentionsumls-concept:C0443268lld:lifeskim
pubmed-article:9449486pubmed:issue10lld:pubmed
pubmed-article:9449486pubmed:dateCreated1998-3-6lld:pubmed
pubmed-article:9449486pubmed:abstractTextA high percentage of extracutaneous CD30+ anaplastic large cell lymphomas (nodal ALCL) carry a specific chromosomal translocation, t(2;5) (p23;q35), that results in abnormal expression of p80 NPM/ALK chimeric protein (p80). The protein p80 may be detected by immunohistochemistry using polyclonal (anti-p80) or monoclonal (ALK1) antibody directed against the ALK epitope. Although nodal ALCL, primary cutaneous ALCL, and lymphomatoid papulosis type A (lyp A) have similar histologic and immunohistochemical features, the expression of p80 in these cutaneous lesions has not been extensively studied. We immunostained tissues from 10 nodal ALCL, 8 primary cutaneous ALCL, 24 lyp A, and positive and negative controls using polyclonal rabbit anti-p80 and the avidin-biotin-peroxidase labeling method. Reactivity was determined by comparing staining intensity to positive controls [4 nodal ALCL with t(2;5)] and negative controls (21 non-ALCL lymphomas). Only cutaneous lesions staining positively with anti-p80 were further studied with the monoclonal antibody ALK1 and reverse transcription polymerase chain reaction (RT-PCR) for p80 messenger RNA. All positive controls (4/4), but none of the negative controls (0/21) nor lyp A (0/24), were immunoreactive for anti-p80. Sixty percent (6/10) of nodal ALCL and a single case (12%) of primary cutaneous ALCL were immunoreactive for anti-p80. In this exceptional cutaneous lesion, although we did not find NPM/ALK by RT-PCR, we detected strong expression of ALK using ALK1. We conclude that t(2;5) is rarely involved in the pathogenesis of cutaneous CD30+ lymphoproliferative disorders.lld:pubmed
pubmed-article:9449486pubmed:languageenglld:pubmed
pubmed-article:9449486pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9449486pubmed:citationSubsetIMlld:pubmed
pubmed-article:9449486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9449486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9449486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9449486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9449486pubmed:statusMEDLINElld:pubmed
pubmed-article:9449486pubmed:monthNovlld:pubmed
pubmed-article:9449486pubmed:issn0303-6987lld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:SchnitzerBBlld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:MoriSSlld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:MasonD YDYlld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:HeadingtonJ...lld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:RossC WCWlld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:ShiotaMMlld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:SingletonT...lld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:VasekJJlld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:PulfordKKlld:pubmed
pubmed-article:9449486pubmed:authorpubmed-author:SuL DLDlld:pubmed
pubmed-article:9449486pubmed:issnTypePrintlld:pubmed
pubmed-article:9449486pubmed:volume24lld:pubmed
pubmed-article:9449486pubmed:ownerNLMlld:pubmed
pubmed-article:9449486pubmed:authorsCompleteYlld:pubmed
pubmed-article:9449486pubmed:pagination597-603lld:pubmed
pubmed-article:9449486pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:meshHeadingpubmed-meshheading:9449486-...lld:pubmed
pubmed-article:9449486pubmed:year1997lld:pubmed
pubmed-article:9449486pubmed:articleTitleThe t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.lld:pubmed
pubmed-article:9449486pubmed:affiliationUniversity of Michigan, Ann Arbor, USA.lld:pubmed
pubmed-article:9449486pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9449486pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9449486lld:pubmed